

Product datasheet for TA351903S

ULBP1 Rabbit Polyclonal Antibody

Product data:

Product Type: Primary Antibodies

Applications: IHC

Recommended Dilution: IHC: 25-100

Positive control: Human breast cancer Predicted cell location: Cytoplasm

Reactivity: Human
Host: Rabbit
Isotype: IgG

Clonality: Polyclonal

Immunogen: Synthetic peptide of human ULBP1

Formulation: pH7.4 PBS, 0.05% NaN3, 40% Glyceroln

Purification: Antigen affinity purification

Conjugation: Unconjugated

Storage: Store at -20°C as received.

Stability: Stable for 12 months from date of receipt.

Gene Name: UL16 binding protein 1

Database Link: NP 079494

Entrez Gene 80329 Human

Q9BZM6

Background: Ligand for the KLRK1/NKG2D receptor, together with at least ULBP2 and ULBP3. ULBPs

activate multiple signaling pathways in primary NK cells, resulting in the production of cytokines and chemokines. Binding of ULBPs ligands to KLRK1/NKG2D induces calcium mobilization and activation of the JAK2, STAT5, ERK and PI3K kinase/Akt signal transduction pathway. In CMV infected cells, interacts with soluble CMV glycoprotein UL16. The interaction with UL16 blocked the interaction with the KLRK1/NKG2D receptor, providing a mechanism by which CMV infected cells might escape the immune system. UL16 also causes ULBP1 to be

retained in the ER and cis-Golgi apparatus so that it does not reach the cell surface.

Synonyms: RAET11



OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200

CN: techsupport@origene.cn


Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com




Protein Families: Druggable Genome, Transmembrane

Protein Pathways: Natural killer cell mediated cytotoxicity

Product images:



Immunohistochemistry of paraffin-embedded Human breast cancer tissue using [TA351903] (ULBP1 Antibody) at dilution 1/25 (Original magnification: ×200)



Immunohistochemistry of paraffin-embedded Human breast cancer tissue using [TA351903] (ULBP1 Antibody) at dilution 1/25, treated with synthetic peptide. (Original magnification: ×200)